An international research team, led by University College London's Professor Jonathan Ledermann, carried out a trial to see
whether olaparib could have a role to play in preventing ovarian cancer from coming back in this group of patients.
Not exact matches
Based on these studies, the authors are designing a clinical trial to test
whether DNA repair inhibitors, such as
olaparib, are active against IDH1 - and IDH2 - mutant tumors.
He is currently leading the TOPARP trial, which is finding out
whether a drug called
olaparib (Lynparza) improves survival for men with advanced prostate cancer that has stopped responding to treatment.